Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications

Current Opinion in Pharmacology

Volumn 13, Issue 2, 2013, Pages 280-286

  Zwadlo, Carolin ^a   Bauersachs, Johann ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANRENOATE POTASSIUM; CANRENONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MINERALOCORTICOID ANTAGONIST; PLACEBO; POTASSIUM; SODIUM; SPIRONOLACTONE;

ACUTE HEART INFARCTION; ALDOSTERONE BLOOD LEVEL; ARTERIAL WALL THICKNESS; BARE METAL STENT; CARDIOVASCULAR INFLAMMATION; CAROTID ATHEROSCLEROSIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFICACY; EARLY INTERVENTION; ENDOTHELIAL DYSFUNCTION; FLUID BALANCE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE RELAXATION; HUMAN; IN-STENT RESTENOSIS; MORBIDITY; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PATHOPHYSIOLOGY; POTASSIUM EXCRETION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SODIUM ABSORPTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANIMALS; CORONARY ARTERY DISEASE; HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIAL INFARCTION;

EID: 84879416649     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.12.007     Document Type: Review

References (43)

1. S. Messaoudi, F. Azibani, C. Delcayre, and F. Jaisser Aldosterone, mineralocorticoid receptor, and heart failure Mol Cell Endocrinol 350 2012 266 272
2. N. Farman, and M.E. Rafestin-Oblin Multiple aspects of mineralocorticoid selectivity Am J Physiol Renal Physiol 280 2001 F181 F192
3. G. Guder, J. Bauersachs, S. Frantz, D. Weismann, B. Allolio, G. Ertl, C.E. Angermann, and S. Stork Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure Circulation 115 2007 1754 1761 (Pubitemid 46648612)
4. D. Fraccarollo, P. Galuppo, S. Hildemann, M. Christ, G. Ertl, and J. Bauersachs Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction J Am Coll Cardiol 42 2003 1666 1673 (Pubitemid 37378451)
5. A. Tomaschitz, S. Pilz, E. Ritz, A. Meinitzer, B.O. Boehm, and W. Marz Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study Eur Heart J 31 2010 1237 1247
6. F. Ivanes, S. Susen, F. Mouquet, P. Pigny, F. Cuilleret, K. Sautiere, J.P. Collet, F. Beygui, B. Hennache, and P.V. Ennezat Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure Eur Heart J 33 2012 191 202
7. T. Amano, T. Matsubara, H. Izawa, M. Torigoe, T. Yoshida, Y. Hamaguchi, H. Ishii, M. Miura, Y. Hayashi, and Y. Ogawa Impact of plasma aldosterone levels for prediction of in-stent restenosis Am J Cardiol 97 2006 785 788
8. O.D. Rita, D.G. Hackam, and J.D. Spence Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque Can J Cardiol 28 2012 706 711
9. A. Vukusich, S. Kunstmann, C. Varela, D. Gainza, S. Bravo, D. Sepulveda, G. Cavada, L. Michea, and E.T. Marusic A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients Clin J Am Soc Nephrol 5 2010 1380 1387
10. J. Suzuki, M. Iwai, M. Mogi, A. Oshita, T. Yoshii, J. Higaki, and M. Horiuchi Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation Arterioscler Thromb Vasc Biol 26 2006 917 921 (Pubitemid 43732172)
11. S. Keidar, T. Hayek, M. Kaplan, E. Pavlotzky, S. Hamoud, R. Coleman, and M. Aviram Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice J Cardiovasc Pharmacol 41 2003 955 963 (Pubitemid 36706146)
12. S. Rajagopalan, D. Duquaine, S. King, B. Pitt, and P. Patel Mineralocorticoid receptor antagonism in experimental atherosclerosis Circulation 105 2002 2212 2216 (Pubitemid 34517167)
13. J.S. Silvestre, C. Heymes, A. Oubenaissa, V. Robert, B. Aupetit-Faisant, A. Carayon, B. Swynghedauw, and C. Delcayre Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis Circulation 99 1999 2694 2701 (Pubitemid 29237459)
14. D. Fraccarollo, P. Galuppo, S. Schraut, S. Kneitz, R.N. van, G. Ertl, and J. Bauersachs Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response Hypertension 51 2008 905 914 (Pubitemid 351654703)
15. D. Fraccarollo, S. Berger, P. Galuppo, S. Kneitz, L. Hein, G. Schutz, S. Frantz, G. Ertl, and J. Bauersachs Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction Circulation 123 2011 400 408
16. A.J. Rickard, J. Morgan, G. Tesch, J.W. Funder, P.J. Fuller, and M.J. Young Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure Hypertension 54 2009 537 543
17. M.G. Usher, S.Z. Duan, C.Y. Ivaschenko, R.A. Frieler, S. Berger, G. Schutz, C.N. Lumeng, and R.M. Mortensen Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice J Clin Invest 120 2010 3350 3364
18. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, and J. Wittes The effect of spironolactone on morbidity and mortality in patients with severe heart failure, Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717 (Pubitemid 29407370)
19. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, and M. Gatlin Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321 (Pubitemid 36384098)
20. C. Adamopoulos, A. Ahmed, R. Fay, M. Angioi, G. Filippatos, J. Vincent, B. Pitt, and F. Zannad Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial Eur J Heart Fail 11 2009 1099 1105
21. A. Ouvrard-Pascaud, Y. Sainte-Marie, J.P. Benitah, R. Perrier, C. Soukaseum, C.A. Nguyen Dinh, A. Royer, Q.K. Le, F. Charpentier, and S. Demolombe Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias Circulation 111 2005 3025 3033 (Pubitemid 40847778)
22. P. Galuppo, and J. Bauersachs Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances Eur J Clin Invest 42 2012 1112 1120
23. P. Bramlage, E. Turgonyi, and G. Montalescot Aldosterone blockade: current research and future trends Eur Heart J Suppl 13 Suppl B 2011 B46 B50
24. F. Beygui, E. Vicaut, P. Ecollan, J. Machecourt, B.E. Van, F. Zannad, and G. Montalescot Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial Am Heart J 160 2010 642 648
25. J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Bohm, K. Dickstein, V. Falk, G. Filippatos, C. Fonseca, and M.A. Gomez-Sanchez ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur J Heart Fail 14 2012 803 869
26. F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, S.J. Pocock, and B. Pitt Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
27. K. Swedberg, F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, H. Shi, J. Vincent, and B. Pitt Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study J Am Coll Cardiol 59 2012 1598 1603
28. J.J. McMurray CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure Eur J Heart Fail 13 2011 929 936
29. A.K. Chan, J.E. Sanderson, T. Wang, W. Lam, G. Yip, M. Wang, Y.Y. Lam, Y. Zhang, L. Yeung, and E.B. Wu Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure J Am Coll Cardiol 50 2007 591 596 (Pubitemid 47199012)
30. A.M. Marney, and N.J. Brown Aldosterone and end-organ damage Clin Sci (Lond) 113 2007 267 278 (Pubitemid 47372685)
31. S. Johar, A.C. Cave, A. Narayanapanicker, D.J. Grieve, and A.M. Shah Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase FASEB J 20 2006 1546 1548
32. J. Favre, J. Gao, A.D. Zhang, I. Remy-Jouet, A. Ouvrard-Pascaud, B. Dautreaux, B. Escoubet, C. Thuillez, F. Jaisser, and V. Richard Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression Am J Physiol Heart Circ Physiol 300 2011 H2035 H2043
33. C.A. Farquharson, and A.D. Struthers Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure Circulation 101 2000 594 597 (Pubitemid 30094728)
34. J. Bauersachs Aldosterone antagonism in heart failure: improvement of cardiac remodelling, endothelial dysfunction and platelet activation Eur J Clin Invest 34 2004 649 652 (Pubitemid 39423021)
35. Z.A. Di, C.A. Nguyen Dinh, C. Soukaseum, B. Escoubet, A. Cherfa, S. Messaoudi, C. Delcayre, J.L. Samuel, and F. Jaisser Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling Hypertension 52 2008 1060 1067
36. E. Harada, M. Yoshimura, H. Yasue, O. Nakagawa, M. Nakagawa, M. Harada, Y. Mizuno, M. Nakayama, Y. Shimasaki, and T. Ito Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes Circulation 104 2001 137 139 (Pubitemid 32655827)
37. A. Boccanelli, G.F. Mureddu, G. Cacciatore, F. Clemenza, L.A. Di, A. Gavazzi, M. Porcu, R. Latini, D. Lucci, and A.P. Maggioni Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results Eur J Heart Fail 11 2009 68 76
38. F. Edelmann, A. Tomaschitz, R. Wachter, G. Gelbrich, M. Knoke, H.D. Dungen, S. Pilz, L. Binder, R. Stahrenberg, and A. Schmidt Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction Eur Heart J 33 2012 203 212
39. P.M. Mottram, B. Haluska, R. Leano, D. Cowley, M. Stowasser, and T.H. Marwick Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure Circulation 110 2004 558 565 (Pubitemid 39031173)
40. A.S. Desai, E.F. Lewis, R. Li, S.D. Solomon, S.F. Assmann, R. Boineau, N. Clausell, R. Diaz, J.L. Fleg, and I. Gordeev Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction Am Heart J 162 2011 966 972
41. F. Edelmann, A.G. Schmidt, G. Gelbrich, L. Binder, C. Herrmann-Lingen, M. Halle, G. Hasenfuss, R. Wachter, and B. Pieske Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF) Eur J Heart Fail 12 2010 874 882
42. Pieske BM: Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure (http://my.americanheart.org/professional/Sessions/AdditionalMeetings/ AdditionalMeetingsResources/Science-News-ESC-2012-Sunday-UCM-443739-Article.jsp)
43. N.M. Albert, C.W. Yancy, L. Liang, X. Zhao, A.F. Hernandez, E.D. Peterson, C.P. Cannon, and G.C. Fonarow Use of aldosterone antagonists in heart failure JAMA 302 2009 1658 1665